Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants

Phase 4

Completed

• Conditions: Brain Cancer
• Interventions: Drug: Sugammadex

• Registration Number: NCT02708056
• Lead Sponsor: Baskent University

Brief Summary

The objective of this study is to evaluate the efficacy and safety of sugammadex in reversing profound neuromuscular block induced by rocuronium in infant patients

Detailed Description

Not available

Study Timeline

• Study Start: 2015-01
• Primary Completion: 2016-02
• Study Completion: 2016-02
• Study First Submitted: 2016-02-25
• Status Verified: 2016-03
• Study First Submitted QC: 2016-03-09
• Last Update Submitted: 2016-03-09
• Study First Posted: 2016-03-15
• Last Update Posted: 2016-03-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

• Patients between the ages of 1-12 month,
• ASA physical status 1-3 who underwent elective brain cancer surgery during general anesthesia were included in the study

Exclusion Criteria

• younger than 1month or older than 12 months.
• hepatic or renal failure
• A history of allergy to study medication

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Sugammadex, Bridion	Sugammadex	Drug were given intravenously by a anesthesiologist at the end of surgery

Primary Outcome Measures

Name	Time	Method
The efficacy of sugammadex were assessed by using Train of four (TOF)	1 year